Cepheid VP sells off company shares; Three Dx tests shine as screens for TB treatment resistance;

> Saladax Biomedical won health department licenses from California, Rhode Island and Maryland to expand MyCare diagnostic testing to gauge a person's optimal chemotherapy dose. Item   

> Cepheid ($CPHD) Vice President David Persing unloaded 20,000 shares of Cepheid stock on Sept. 6 and now directly owns 177 shares in the company. Story

> The first in-vitro diagnostics control laboratory in West Africa launched recently in Nigeria. Story

> Three rapid diagnostic tests show promise as an alternative to standard assays used to test for drug resistance in tuberculosis patients. Item

> Advanced Biological Laboratories in Luxembourg signed a collaboration deal with Roche Diagnostics International to promote ABL next-generation sequencing technology in Europe, the Middle East, Africa and Latin America. Item